169 related articles for article (PubMed ID: 9058624)
1. Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis.
de Caestecker JS
Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):145-7. PubMed ID: 9058624
[TBL] [Abstract][Full Text] [Related]
2. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic acid and immunosuppressive therapy.
Lim AG; Wolfhagen FH; Verma A; van Buuren HR; Jazrawi RP; Levy JH; Northfield TC; Schalm SW
Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):155-61. PubMed ID: 9058626
[TBL] [Abstract][Full Text] [Related]
3. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
4. Development of autoimmune hepatitis in primary biliary cirrhosis.
Gossard AA; Lindor KD
Liver Int; 2007 Oct; 27(8):1086-90. PubMed ID: 17845536
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
6. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study.
Wolfhagen FH; van Hoogstraten HJ; van Buuren HR; van Berge-Henegouwen GP; ten Kate FJ; Hop WC; van der Hoek EW; Kerbert MJ; van Lijf HH; den Ouden JW; Smit AM; de Vries RA; van Zanten RA; Schalm SW
J Hepatol; 1998 Nov; 29(5):736-42. PubMed ID: 9833911
[TBL] [Abstract][Full Text] [Related]
7. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
Fang YQ; Lv DX; Jia W; Li J; Deng YQ; Wang Y; Yu M; Wang GQ
Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
[TBL] [Abstract][Full Text] [Related]
8. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
Silveira MG; Lindor KD
Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
[TBL] [Abstract][Full Text] [Related]
9. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
10. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
11. The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis.
Kaplan MM
Semin Liver Dis; 1997 May; 17(2):129-36. PubMed ID: 9170200
[TBL] [Abstract][Full Text] [Related]
12. [Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome: therapeutic features in 5 patients].
Cheikh I; Said Y; Chaabouni H; Ouerghi H; Ben Ammar A
Ann Med Interne (Paris); 2003 Feb; 154(1):7-11. PubMed ID: 12746654
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune liver disease. Current standards, future directions.
Gish RG; Mason A
Clin Liver Dis; 2001 May; 5(2):287-314. PubMed ID: 11385965
[TBL] [Abstract][Full Text] [Related]
14. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
15. Primary biliary cirrhosis.
Rinella ME
Ann Hepatol; 2006; 5(3):198-200. PubMed ID: 17060882
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil for primary biliary cirrhosis--convergent thinking.
Altschuler EL
Eur J Gastroenterol Hepatol; 2000 May; 12(5):587. PubMed ID: 10833107
[No Abstract] [Full Text] [Related]
17. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
18. Management of autoimmune and cholestatic liver disorders.
Krok KL; Munoz SJ
Clin Liver Dis; 2009 May; 13(2):295-316. PubMed ID: 19442920
[TBL] [Abstract][Full Text] [Related]
19. [Primary biliary cirrhosis].
Corpechot C
Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):320-4. PubMed ID: 12700520
[No Abstract] [Full Text] [Related]
20. [Budesonide in treatment of patients with cross primary biliary cirrhosis and autoimmune hepatitis].
Golovanova EV; Khomeriki SG; Petrakov AV; Serova TI
Eksp Klin Gastroenterol; 2010; (8):113-7. PubMed ID: 21268335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
